Merck KGaA has confirmed that it is in discussions for a potential acquisition of SpringWorks Therapeutics, Inc., a U.S.-based biotech firm. This move is part of Merck's strategy to enhance its oncology portfolio. The acquisition discussions follow SpringWorks' recent FDA approval for its cancer drug, mirdametinib (brand name Gomekli), which is indicated for adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas. The approval includes a priority review voucher, fast track designation, and orphan drug designation, bolstering SpringWorks' position in the market. Analysts speculate that a deal could significantly strengthen Merck's pharmaceutical division, although specific terms of the potential acquisition remain unclear.